{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T12:32:03Z","timestamp":1717072323600},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"DOI":"10.1093\/jjco\/hyy001","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T21:25:24Z","timestamp":1515533124000},"page":"248-254","source":"Crossref","is-referenced-by-count":2,"title":["Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors"],"prefix":"10.1093","volume":"48","author":[{"given":"Yoko","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, Saitama Cancer Center, Saitama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Tokudome","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyoundo Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yamagata University Hospital, Yamagata"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kashiwabara","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Graduate School of Medicine, the University of Tokyo, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"key\n\t\t\t\t20180830004415_hyy001C1","author":"Cancer Information","year":"2016"},{"key":"key\n\t\t\t\t20180830004415_hyy001C2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jjco\/hyv088","article-title":"Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project","volume":"45","author":"Hori","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative G","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180830004415_hyy001C4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180830004415_hyy001C5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/bcr3636","article-title":"Status of adjuvant endocrine therapy for breast cancer","volume":"16","author":"Schiavon","year":"2014","journal-title":"Breast Cancer Res"},{"key":"key\n\t\t\t\t20180830004415_hyy001C6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative G","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180830004415_hyy001C7","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180830004415_hyy001C8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180830004415_hyy001C9","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180830004415_hyy001C10","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1\u201398 randomised clinical trial at 8.1 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180830004415_hyy001C13","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180830004415_hyy001C14","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C15","author":"NCCN","year":"2016"},{"key":"key\n\t\t\t\t20180830004415_hyy001C16","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ijc.11661","article-title":"The increase of female breast cancer incidence in Japan: emergence of birth cohort effect","volume":"108","author":"Minami","year":"2004","journal-title":"Int J Cancer"},{"key":"key\n\t\t\t\t20180830004415_hyy001C18","first-page":"879","article-title":"Comparison of trends in cancer incidence and mortality in Osaka, Japan, using an age-period-cohort model","volume":"12","author":"Ito","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"key\n\t\t\t\t20180830004415_hyy001C19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/annonc\/mdq596","article-title":"Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis","volume":"22","author":"Yamashita","year":"2011","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.11859","article-title":"Is breast cancer survival improving?","volume":"100","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180830004415_hyy001C21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF02967531","article-title":"Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)","volume":"8","author":"Umemura","year":"2001","journal-title":"Breast Cancer"},{"key":"key\n\t\t\t\t20180830004415_hyy001C22","author":"HER2","year":"2009"},{"key":"key\n\t\t\t\t20180830004415_hyy001C23","author":"trastuzumab PCfOuo HER2","year":"2014"},{"key":"key\n\t\t\t\t20180830004415_hyy001C24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C25","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key\n\t\t\t\t20180830004415_hyy001C27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12282-015-0599-6","article-title":"Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011","volume":"22","author":"Kurebayashi","year":"2015","journal-title":"Breast Cancer"},{"key":"key\n\t\t\t\t20180830004415_hyy001C28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/jamaoncol.2015.3062","article-title":"Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis","volume":"1","author":"Fujii","year":"2015","journal-title":"JAMA Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative G.","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180830004415_hyy001C30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180830004415_hyy001C31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2010.34.4010","article-title":"Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover","volume":"30","author":"Jin","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10549-009-0630-8","article-title":"Fifteen-year trends in metastatic breast cancer survival in Greece","volume":"119","author":"Dafni","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"key\n\t\t\t\t20180830004415_hyy001C33","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2004.08.095","article-title":"Breast cancer with synchronous metastases: trends in survival during a 14-year period","volume":"22","author":"Andre","year":"2004","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830004415_hyy001C34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180830004415_hyy001C35","article-title":"Preoperative chemotherapy for women with operable breast cancer","author":"Mieog","year":"2007","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/48\/3\/248\/25535564\/hyy001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T05:18:00Z","timestamp":1570598280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/48\/3\/248\/4827914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,1,29]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyy001","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2018,1,29]]}}}